Zynyz (retifanlimab-dlwr) - Incyte
Advanced Merkel cell carcinoma: High unmet medical need and clinical insights from the POD1UM-201 study of retifanlimab (ADO 2026) - Sep 7, 2026 - Pres time: Sep 11, 2026; 04:45 PM - 05:15 PM; Location: Schiller Hall; "Sponsored by Incyte Biosciences Germany GmbH" 
Clinical • Metastases • Merkel Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor
https://programme.conventus.de/ado-2026/program/program-points/7b62cc12-806f-4d5e-81ff-69a5ffc2d5c0
 
Prof. Ralf Gutzmer
 
Sep 7, 2026
 
Prev Next